title: Intravitreal bevacizumab for retinopathy of prematurity: Considerations for informed consent.
authors.affiliation: The Hospital for Sick Children, Department of Ophthalmology and Visual Sciences, Toronto, ON. Electronic address: Kamiar.mireskandari@sickkids.ca.
authors.forename: Kamiar
authors.initials: K
authors.lastname: Mireskandari
authors.affiliation: The Hospital for Sick Children, Department of Ophthalmology and Visual Sciences, Toronto, ON; Wilmer Eye Institute, Johns Hopkins School of Medicine, Baltimore, MD.
authors.forename: Megan E
authors.initials: ME
authors.lastname: Collins
authors.affiliation: The Hospital for Sick Children, Department of Ophthalmology and Visual Sciences, Toronto, ON.
authors.forename: Nasrin
authors.initials: N
authors.lastname: Tehrani
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007258:Informed Consent; D058449:Intravitreal Injections; D017410:Practice Guidelines as Topic; D012178:Retinopathy of Prematurity / Q000188:drug therapy*; D012307:Risk Factors; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab